Addressing potential bias when assessing safety of biologics and JAK inhibitors in atopic dermatitis

J Eur Acad Dermatol Venereol. 2026 Jan 31. doi: 10.1111/jdv.70338. Online ahead of print.

Authors

Lian F van der Gang¹, Keneshka Atash¹, Nicolaas P A Zuithoff², Inge M Haeck¹, Marlies de Graaf¹, Marjolein S de Bruin-Weller¹; all coauthors

Affiliations

¹ Department of Dermatology and Allergology, National Expertise Centre for Atopic Dermatitis, University Medical Centre Utrecht, Utrecht, the Netherlands.
² Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, the Netherlands.

PMID: 41619228
DOI: 10.1111/jdv.70338

No abstract available

Keywords: JAK inhibitors; atopic dermatitis; biologics; infection; real‐world evidence; safety.

Publication types

Letter